OBJECTIVES: Uridine abrogates mitochondrial toxicities of nucleoside reverse transcriptase inhibitor in adipocyte cell culture. We aim to study the effect of uridine supplementation on human adipocyte mitochondrial DNA (mtDNA) levels in subjects with human immunodeficiency (HIV) lipoatrophy. METHODS:Sixteen patients with lipoatrophy on stavudine-containing antiretroviral therapy were enrolled, and receivedNucleomaxX, a dietary supplement with a high bioavailability of uridine (36 g TID every other day for 16 weeks). Patients were then followed off-uridine for another 16 weeks. Highly active antiretroviral therapy remained unchanged during the trial. RESULTS:Fourteen patients completed the study. Two subjects dropped out before week 4 for study-unrelated reasons. No adverse events were noted throughout the study. HIV-1 RNA, CD4 counts, liver enzymes and hemoglobin remained unchanged. Body mass index, lactate, lipids, insulin and homeostasis model assessment of insulin resistance were unaltered. Fat and peripheral blood and mononuclear cellmtDNA levels did not correlate with each other and exhibited no changes throughout the study. Lipoatrophy scores by patients and physician improved significantly at weeks 16 and 32 compared to study entry. CONCLUSION: In this pilot study, NucleomaxX was safe, well tolerated without apparent deleterious effect on HIV indices. In contrast to in vitro data, NucleomaxX did not lead to changes in fat or blood mtDNA levels.
RCT Entities:
OBJECTIVES:Uridine abrogates mitochondrial toxicities of nucleoside reverse transcriptase inhibitor in adipocyte cell culture. We aim to study the effect of uridine supplementation on human adipocyte mitochondrial DNA (mtDNA) levels in subjects with humanimmunodeficiency (HIV) lipoatrophy. METHODS: Sixteen patients with lipoatrophy on stavudine-containing antiretroviral therapy were enrolled, and received NucleomaxX, a dietary supplement with a high bioavailability of uridine (36 g TID every other day for 16 weeks). Patients were then followed off-uridine for another 16 weeks. Highly active antiretroviral therapy remained unchanged during the trial. RESULTS: Fourteen patients completed the study. Two subjects dropped out before week 4 for study-unrelated reasons. No adverse events were noted throughout the study. HIV-1 RNA, CD4 counts, liver enzymes and hemoglobin remained unchanged. Body mass index, lactate, lipids, insulin and homeostasis model assessment of insulin resistance were unaltered. Fat and peripheral blood and mononuclear cell mtDNA levels did not correlate with each other and exhibited no changes throughout the study. Lipoatrophy scores by patients and physician improved significantly at weeks 16 and 32 compared to study entry. CONCLUSION: In this pilot study, NucleomaxX was safe, well tolerated without apparent deleterious effect on HIV indices. In contrast to in vitro data, NucleomaxX did not lead to changes in fat or blood mtDNA levels.
Authors: David Nolan; Emma Hammond; Annalise Martin; Louise Taylor; Susan Herrmann; Elizabeth McKinnon; Cecily Metcalf; Bruce Latham; Simon Mallal Journal: AIDS Date: 2003-06-13 Impact factor: 4.177
Authors: Véronique Joly; Philippe Flandre; Vincent Meiffredy; Nicolas Leturque; Marine Harel; Jean-Pierre Aboulker; Patrick Yeni Journal: AIDS Date: 2002-12-06 Impact factor: 4.177
Authors: Graeme J Moyle; Caroline A Sabin; Jonathan Cartledge; Margaret Johnson; Edmund Wilkins; Duncan Churchill; Philip Hay; Ade Fakoya; Maurice Murphy; George Scullard; Clifford Leen; Geraldine Reilly Journal: AIDS Date: 2006-10-24 Impact factor: 4.177
Authors: Allison Martin; Don E Smith; Andrew Carr; Clare Ringland; Janaki Amin; Sean Emery; Jennifer Hoy; Cassy Workman; Nicholas Doong; Judith Freund; David A Cooper Journal: AIDS Date: 2004-04-30 Impact factor: 4.177
Authors: Grace A McComsey; Douglas J Ward; Siegrid M Hessenthaler; Michael G Sension; Peter Shalit; J Tyler Lonergan; Robin L Fisher; Vanessa C Williams; Jaime E Hernandez Journal: Clin Infect Dis Date: 2003-12-18 Impact factor: 9.079
Authors: Grace A McComsey; Ulrich A Walker; Chakra B Budhathoki; Zhaohui Su; Judith S Currier; Lisa Kosmiski; Linda G Naini; Stéphannie Charles; Kathy Medvik; Judith A Aberg Journal: AIDS Date: 2010-10-23 Impact factor: 4.177
Authors: Marisa Tungsiripat; Mary Ann O'Riordan; Norma Storer; Danielle Harrill; Jason Ganz; Daniel Libutti; Mariana Gerschenson; Grace A McComsey Journal: HIV Clin Trials Date: 2009 Sep-Oct
Authors: S Selvaraj; M Ghebremichael; M Li; Y Foli; A Langs-Barlow; A Ogbuagu; L Barakat; E Tubridy; R Edifor; W Lam; Y-C Cheng; E Paintsil Journal: Clin Pharmacol Ther Date: 2014-03-17 Impact factor: 6.875